Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Approvals Augment Advances Made in the DLBCL Armamentarium

August 11th 2020

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.

Dr. Jacobson on the Interim Analysis of the MZL Cohort in the ZUMA-5 Trial

August 11th 2020

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

ASH Releases Evidence-Based Guidelines for Treating Older Patients With AML

August 10th 2020

The American Society of Hematology has published new evidence-based guidelines to support older patients with acute myeloid leukemia and their health care providers in guiding treatment decisions.

The Future of Multiple Myeloma

August 10th 2020

Targeted Treatment Options in Multiple Myeloma

August 10th 2020

Trials in Relapsed/Refractory Multiple Myeloma

August 10th 2020

Treatment Options in Relapsed/Refractory Multiple Myeloma

August 10th 2020

Options for Transplant Ineligible Patients in Multiple Myeloma

August 10th 2020

Maintenance Therapy in Multiple Myeloma

August 10th 2020

The Role of Transplant in Multiple Myeloma

August 10th 2020

Looking at GRIFFIN Trial Data

August 10th 2020

A Look at the ENDURANCE Trial

August 10th 2020

Newly Diagnosed Multiple Myeloma

August 10th 2020

Introduction to Multiple Myeloma

August 10th 2020

Interim REFLECT Analysis Reconfirms Efficacy, Safety of Rituximab Biosimilar in DLBCL

August 7th 2020

Manfred Welslau, MD, discusses findings from the REFLECT interim analysis that reconfirmed the activity of the rituximab biosimilar SDZ-RTX, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with diffuse large B-cell lymphoma.

Dr. Raje on Efficacy With Melflufen in Triple-Refractory Myeloma

August 6th 2020

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

CD30-Targeted CAR T-Cell Therapy Elicits Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

August 6th 2020

A CD30-targeted CAR T-cell therapy was found to elicit a high rate of durable complete responses (CRs) in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Dr. Balzarotti on Questions With Consolidation and Maintenance Therapy in R/R DLBCL

August 5th 2020

Monica Balzarotti, MD, discusses remaining questions regarding consolidation and maintenance therapy in relapsed/refractory diffuse large B-cell lymphoma.

Shaughnessy Speaks to the Rapidly Evolving Role of CAR T-cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.